Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
Part of paid clinical trials in Nashville, Tennessee.
- Sponsor
- Sanofi
- Study ID
- NCT00692640
- Phase
- PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- XL147 (SAR245408) — DRUGGelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
- Erlotinib — DRUGTablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
Study Details
The purpose of this study is to evaluate the safety and tolerability of XL147 in combination with erlotinib (Tarceva®) in subjects with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells. Erlotinib is an orally administered inhibitor of EGFR (also known as HER1) tyrosine kinase. It was approved by the FDA as a single agent for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen and in combination with gemcitabine for first line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Key Dates
- First listed
- Jun 6, 2008
- Start date
- May 31, 2008
- Status verified
- Mar 2012
- Primary completion
- Nov 30, 2011
- Completion
- Nov 30, 2011
Study Design
- Enrollment
- 35 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: 1
Primary Outcome Measure
Safety, tolerability, and maximum tolerated dose of XL147 administered in combination with erlotinib [ Time Frame: Assessed during periodic visits ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Investigational Site Number 1214 | Nashville | Tennessee | 37203 | - |
Find similar trials in Nashville, TN
Related Studies
- Establishment of a Lifetime of Cohort of Adults Surviving Childhood CancerRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Childhood Cancer Survivor StudyRecruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
- Caris Biorepository Research ProtocolRecruiting · Caris Science, Inc. · Mobile, Alabama
- Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-upRecruiting · Center for Biomedical Research, LLC · Jacksonville, Florida